Ellis Andrea 4
4 · BridgeBio Pharma, Inc. · Filed Apr 3, 2025
Insider Transaction Report
Form 4
Ellis Andrea
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-04-01−30,000→ 74,921 totalExercise: $8.45Exp: 2032-06-22→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2025-04-01$8.45/sh+30,000$253,500→ 42,000 total - Sale
Common Stock
2025-04-01$34.05/sh−30,000$1,021,500→ 12,000 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.
- [F2]The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.